Loading...
Transfusion independence, hematological improvement and associated safety outcomes with bexmarilimab and azacitidine in HR-MDS: results of the bexmab phase 1/2 study
Kontro, M. Stein, A. S. Rimpiläinen, J. Pyörälä, M. Siitonen, T. Ball, B. Myllymäki, M. Zeidner, J. Searle, E. Witherall, R.
Kontro, M.
Stein, A. S.
Rimpiläinen, J.
Pyörälä, M.
Siitonen, T.
Ball, B.
Myllymäki, M.
Zeidner, J.
Searle, E.
Witherall, R.
Abstract
Description
Date
2025
Publisher
Collections
Files
Loading...
Found from Unpaywall
Adobe PDF, 171.83 KB
Keywords
Type
Article
Citation
Kontro M, Stein AS, Rimpiläinen J, Pyörälä M, Siitonen T, Ball B, et al. Transfusion independence, hematological improvement and associated safety outcomes with bexmarilimab and azacitidine in HR-MDS: results of the bexmab phase 1/2 study. Blood. 2025 NOV 3;146:5627-8.